Viekira Pak Results Reassuring for Compensated CirrhosisViekira Pak Results Reassuring for Compensated Cirrhosis

For patients with genotype 1 hepatitis C infection and cirrhosis, the combination of ombitasvir, paritaprevir, and ritonavir plus dasabuvir, with or without ribavirin, is safe and effective. Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Related Links:

ConclusionThe study concluded that the percentage of school students (aged 12–18) years old who are probably infected with HCV was 0.7% (5 out of 750) in Minia district.
Source: Egyptian Pediatric Association Gazette - Category: Pediatrics Source Type: research
Publication date: Available online 12 July 2018Source: The Brazilian Journal of Infectious DiseasesAuthor(s): Norma Arteiro Filgueira, Camilla Maria de Alencar Saraiva, Norma Thomé Jucá, Matheus Filgueira Bezerra, Claudio Moura LacerdaAbstractSchistosomiasis affects approximately 207 million people in 76 countries. The association between hepatocellular carcinoma (HCC) and Schistosoma mansoni infection (SMI) has been investigated. Studies using animal models suggest that the parasite may accelerate the oncogenic process when combined with other factors, such as hepatitis C virus infection or exposure to a car...
Source: The Brazilian Journal of Infectious Diseases - Category: Infectious Diseases Source Type: research
In conclusion, this is a successful case of a hybrid operation for an extremely large and complicated portosystemic shunt, providing for intraoperative angiography as a safe and reliable surgical treatment for portosystemic encephalopathy in patients with liver cirrhosis. PMID: 29986123 [PubMed - in process]
Source: Hiroshima Journal of Medical Sciences - Category: General Medicine Tags: Hiroshima J Med Sci Source Type: research
ConclusionsNRP1 is a novel tumor marker in HCC.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Conclusion: This study demonstrated that GDF15 and AFP detection can help in the diagnosis and prediction of complications associated with CHC including liver cirrhosis and HCC. Also GDF15 can be used as a satisfactory serum marker of HCC and LC.
Source: Journal of Genetic Engineering and Biotechnology - Category: Biotechnology Source Type: research
Publication date: June 2018Source: Beni-Suef University Journal of Basic and Applied Sciences, Volume 7, Issue 2Author(s): Samah S. Abdel Gawad, Enas Yahia Abu-Sarea, Lamiaa SalehAbstractSchistosomiasis and hepatitis C virus (HCV) are endemic diseases with high prevalence in Africa especially in Egypt. Many sociodemographic and behavioral related determinants were implicated to be associated with schistosomiasis, HCV or coinfection. Recently, polymerase chain reaction (PCR) is used as a diagnostic tool as it is a sensitive and a specific method especially in early stage of infection. But, diagnosis of S. mansoni is dependi...
Source: Beni Suef University Journal of Basic and Applied Sciences - Category: Science Source Type: research
Publication date: Available online 18 January 2016Source: Respiratory Medicine Case ReportsAuthor(s): Samuel C. Owen, Danielle R. Bersabe, Andrew J. Skabelund, Edward T. McCann, Michael J. MorrisAbstractA patient with long-standing cirrhosis due to hepatitis C and hepatic hydrothorax was evaluated for increasing symptoms and presence of a large right pleural effusion. Thoracentesis revealed evidence of a chylothorax with rapid reaccumulation of pleural fluid. Repeat thoracentesis with manometry identified presence of entrapped lung which complicated treatment options. This is the first case report of a hepatic chylothorax ...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
Publication date: Available online 21 June 2018Source: Journal of Clinical and Experimental HepatologyAuthor(s): Gyanranjan Rout, Baibaswata Nayak, Arpan H. Patel, Deepak Gunjan, Vishwajeet Singh, Saurabh Kedia, ShalimarBackground/AimsDirect-Acting Antivirals (DAAs) are now the standard of care for management of Chronic Hepatitis C (CHC) infection. The aim of this study was to evaluate change in Liver Stiffness Measurement (LSM) and Controlled Attenuation Parameter (CAP) by transient elastography (FibroScan®) after completion of DAA therapy.MethodsLSM and CAP were measured serially (baseline pre-treatment, at 12 weeks ...
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
ConclusionOur data suggest that sofosbuvir based therapy is effective in patients with ESRD and hepatitis C, including those with liver cirrhosis. Its use may be recommended especially in countries where other drugs are not available. Due to limited experience however, patients should be closely monitored for adverse effects. Hypoglycemia may be a potential adverse effect of sofosbuvir and daclatasvir therapy.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
Publication date: June 2018Source: Journal of Clinical and Experimental Hepatology, Volume 8, Issue 2Author(s): Xuan Guo, Jin-Yi Zhong, Jun-Wen LiIn the twenty-seven years since the discovery of hepatitis C virus (HCV) the majority of individuals exposed to HCV establish a persistent infection, which is a leading cause of chronic liver disease, cirrhosis and hepatocellular carcinoma. In developed nations, the cure rates of HCV infection could be over 90% with direct-acting antiviral (DAA) regimens, which has made the great progress in global eradication. However, the cost of these treatments is so expensive that the patien...
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
More News: Cirrhosis | Gastroenterology | Hepatitis | Hepatitis C | Norvir